Bionano Genomics, Inc.

As of June 30, 2026, Bionano Genomics, Inc. carries a market capitalization of 235.43M, placing it among publicly traded companies globally. Its enterprise value stands at 179.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bionano Genomics, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Bionano Genomics, Inc. has 11.78M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.41, and the price-to-book ratio stands at 0.43.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 179.26M versus a market cap of 235.43M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bionano Genomics, Inc. maintains a current ratio of 2.48, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.21, indicating elevated leverage, while an interest coverage ratio of -27.34 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bionano Genomics, Inc. posted a negative return on equity (ROE) of -83.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -52.04, reflecting losses generated across the asset base. The company generates approximately 5.39M in revenue per employee across its workforce of 97.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.29 indicates how many times Bionano Genomics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bionano Genomics, Inc. recorded 1.15M in income tax expense. The company reported a pretax loss of -560.77M and -561.92M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Bionano Genomics, Inc.'s stock has declined approximately 33.80% over the past 52 weeks. The 50-day moving average sits at 24.68, while the 200-day moving average is 268.26.

Over the twelve months ended June 30, 2026, Bionano Genomics, Inc. generated 527.22M in revenue and converted that into -561.92M in net income, yielding earnings per share of -52.28. EBITDA reached -396.01M, while operating income came in at -562.39M.

As of June 30, 2026, Bionano Genomics, Inc. holds 173.30M in cash and equivalents against 117.13M in total debt, resulting in a net debt position of -65.17M. Total book value stands at 552.21M, with working capital of 259.26M providing operational flexibility.

Bionano Genomics, Inc. produced -357.82M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -357.82M - equivalent to -33.29 per share.

Over the twelve months ended June 30, 2026, Bionano Genomics, Inc. posted a gross margin of 47.50, reflecting its pricing power and cost economics. The operating margin of -106.67 and net profit margin of -106.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -166.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.61, meaning Bionano Genomics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Bionano Genomics, Inc.'s most recent stock split took place on January 27, 2025 with a 60:1 split ratio.

As of June 30, 2026, Bionano Genomics, Inc. has an Altman Z-Score of -23.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.